Top

Published in:

Open Access 01-03-2013 | Original Paper

CD33⁺/p-STAT1⁺ double-positive cell as a prognostic factor for stage IIIa gastric cancer

Authors: Jun Dong, Jiao Li, Shi-Ming Liu, Xing-Yu Feng, Shi Chen, Ying-Bo Chen, Xiao-Shi Zhang

Published in: Medical Oncology | Issue 1/2013

Abstract

Tumor-infiltrating immune cells are associated with tumor prognosis, although the type of immune cells responsible for local immune escape is still unknown. This study examined the relationship between gastric cancer survival and the density of immune cells, including CD8⁺ T cells, CD20⁺ B cells, and CD33⁺/p-STAT1⁺ cells, which represent myeloid-derived suppressor cells, to evaluate the role of immune cells in the progression of gastric cancer. One hundred pathologically confirmed specimens were obtained from stage IIIa gastric cancers between 2003 and 2006 at Sun Yat-sen University Cancer Center, China. The density of tumor-infiltrating immune cells in tumor tissue was examined using immunohistochemical analysis. Clinicopathologic parameters and the survival rate were analyzed in relation to the density of immune cells. A high density of CD8⁺ T cells and CD20⁺ B cells was associated with a good clinical outcome, but a high density of CD33⁺/p-STAT1⁺ cells was associated with a poor clinical outcome. Most importantly, the density of CD33⁺/p-STAT1⁺ cells was an independent prognostic factor and inversely related to the infiltration of CD8⁺ T cells. Although the infiltration of CD8⁺ T cells and CD20⁺ B cells is involved in the progression of gastric cancer, these data suggest that CD33⁺/p-STAT1⁺ cells play a central role in the regulation of the local immune response, suggesting that CD33⁺/p-STAT1⁺ cells might be therapeutic targets in gastric cancer.

Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.PubMed

Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5(Suppl 1):5–11.PubMedCrossRef

Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12(1):17–20.PubMed

Parkin DM. International variation. Oncogene. 2004;23(38):6329–40. doi:10.1038/sj.onc.1207726.PubMedCrossRef

Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. doi:10.1056/NEJMoa1104621.PubMedCrossRef

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.PubMedCrossRef

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690.PubMedCrossRef

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. doi:10.1056/NEJMoa1200694.PubMedCrossRef

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.PubMedCrossRef

10.

Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. 2011;167(2):207–10. doi:10.1016/j.jss.2009.08.029.PubMedCrossRef

11.

Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev. 2012;38(5):451–66. doi:10.1016/j.ctrv.2011.09.001.PubMedCrossRef

12.

Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. doi:10.1038/bjc.2011.189.PubMedCrossRef

13.

Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245.PubMedCrossRef

14.

Peng RQ, Wu XJ, Ding Y, Li CY, Yu XJ, Zhang X, et al. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer. 2010;10:496. doi:10.1186/1471-2407-10-496.PubMedCrossRef

15.

Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, Ding Y, et al. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med. 2010;8:13. doi:10.1186/1479-5876-8-13.PubMedCrossRef

16.

Rosenberg SA. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med. 1996;47:481–91. doi:10.1146/annurev.med.47.1.481.PubMedCrossRef

17.

Menegaz RA, Michelin MA, Etchebehere RM, Fernandes PC, Murta EF. Peri- and intratumoral T and B lymphocytic infiltration in breast cancer. Eur J Gynaecol Oncol. 2008;29(4):321–6.PubMed

18.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–8. doi:10.1200/JCO.2010.30.5425.PubMedCrossRef

19.

Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61(13):5132–6.PubMed

20.

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113(6):1387–95. doi:10.1002/cncr.23712.PubMedCrossRef

21.

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429–40. doi:10.1053/j.gastro.2009.10.057.PubMedCrossRef

22.

Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71(17):5670–7. doi:10.1158/0008-5472.CAN-11-0268.PubMedCrossRef

23.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000–9. doi:10.1158/0008-5472.CAN-08-2360.PubMedCrossRef

24.

Zhang YL, Li J, Mo HY, Qiu F, Zheng LM, Qian CN, et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer. 2010;9:4. doi:10.1186/1476-4598-9-4.PubMedCrossRef

25.

Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE. 2009;4(7):e6412. doi:10.1371/journal.pone.0006412.PubMedCrossRef

26.

Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132(2):545–53. doi:10.1007/s10549-011-1620-1.PubMedCrossRef

27.

Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother. 2006;55(3):237–45. doi:10.1007/s00262-005-0048-z.PubMedCrossRef

28.

Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13(18 Pt 1):5243–8. doi:10.1158/1078-0432.CCR-07-0182.PubMedCrossRef

29.

Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802.PubMed

30.

Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155–66. doi:10.1172/JCI31422.PubMedCrossRef

31.

Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64(17):6337–43. doi:10.1158/0008-5472.CAN-04-0757.PubMedCrossRef

32.

Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150–66.PubMed

33.

Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8⁺ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162(10):5728–37.PubMed

34.

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546–53. doi:10.1200/JCO.2006.08.5829.PubMedCrossRef

35.

Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111(1):219–28. doi:10.1182/blood-2007-04-086835.PubMedCrossRef

36.

Yang L, Moses HL. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res. 2008;68(22):9107–11. doi:10.1158/0008-5472.CAN-08-2556.PubMedCrossRef

37.

Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67(23):11438–46. doi:10.1158/0008-5472.CAN-07-1882.PubMedCrossRef

38.

Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6(4):409–21. doi:10.1016/j.ccr.2004.08.031.PubMedCrossRef

39.

Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+ CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13(1):23–35. doi:10.1016/j.ccr.2007.12.004.PubMedCrossRef

40.

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74. doi:10.1038/nri2506.PubMedCrossRef

41.

Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174(8):4880–91.PubMed

42.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8⁺ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491–4.PubMed

43.

Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol. 2001;159(1):297–304. doi:10.1016/S0002-9440(10)61695-1.PubMedCrossRef

44.

Oberg A, Samii S, Stenling R, Lindmark G. Different occurrence of CD8⁺, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis. 2002;17(1):25–9.PubMedCrossRef

45.

Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8⁺ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10(2):309–13.PubMed

46.

Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic role of CD8⁺ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 2004;35(7):808–16.PubMedCrossRef

47.

Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004;84(4):493–501. doi:10.1038/labinvest.3700055.PubMedCrossRef

48.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. doi:10.1126/science.1129139.PubMedCrossRef

49.

Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8(12):711–9. doi:10.1038/nrclinonc.2011.122.PubMedCrossRef

50.

Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16):5220–7. doi:10.1158/1078-0432.CCR-08-0133.PubMedCrossRef

51.

Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99(10):1704–11. doi:10.1038/sj.bjc.6604738.PubMedCrossRef

52.

Matsutani T, Shiiba K, Yoshioka T, Tsuruta Y, Suzuki R, Ochi T, et al. Evidence for existence of oligoclonal tumor-infiltrating lymphocytes and predominant production of T helper 1/T cytotoxic 1 type cytokines in gastric and colorectal tumors. Int J Oncol. 2004;25(1):133–41.PubMed

53.

Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73(3–4):215–20. doi:10.1159/000127412.PubMedCrossRef

54.

Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells. J Clin Invest. 2006;116(10):2777–90. doi:10.1172/JCI28828.PubMedCrossRef

55.

Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8⁺ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175(7):4583–92.PubMed

Title: CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer
Authors: Jun Dong
Jiao Li
Shi-Ming Liu
Xing-Yu Feng
Shi Chen
Ying-Bo Chen
Xiao-Shi Zhang
Publication date: 01-03-2013
Publisher: Springer US
Published in: Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-012-0442-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

CD33⁺/p-STAT1⁺ double-positive cell as a prognostic factor for stage IIIa gastric cancer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma

AC133 expression associated with poor prognosis in stage II colorectal cancer

Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer

Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma

HLA-G expression in acute lymphoblastic leukemia: a significant prognostic tumor biomarker

Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page